Lingyan Jiang

Company: Revolution Medicines Inc.

Job title: Senior Scientist II

Seminars:

RMC-9805, a First-in-Class, Mutant-Selective Covalent and Orally Bioavailable KRASG12D(ON) Inhibitor that Induces Apoptosis and Drives Tumor Regression in Preclinical Models of KRASG12D Cancers 2:00 pm

RMC-9805 is a first-in-class, orally bioavailable, and mutant-selective covalent inhibitor of the GTP-bound and active RAS(ON) form of KRASG12D, and drove durable regressions in preclinical KRASG12D cancer models across indications. RMC-9805 is a CNS-penetrant inhibitor and demonstrated significant anti-tumor activity in both orthotopic and intracranial xenograft models of human KRASG12D cancers. RMC-9805 promotes cancer-associated neoantigen…Read more

day: Day One Track B PM